These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21651490)

  • 1. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview.
    Sartini S; Dario B; Morelli M; Da Settimo F; La Motta C
    Curr Med Chem; 2011; 18(19):2893-903. PubMed ID: 21651490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).
    Maleddu A; Pantaleo MA; Nannini M; Di Battista M; Saponara M; Lolli C; Biasco G
    Oncol Rep; 2009 Jun; 21(6):1359-66. PubMed ID: 19424610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Keretsu S; Ghosh S; Cho SJ
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design.
    Kissova M; Maga G; Crespan E
    Bioorg Med Chem; 2016 Oct; 24(19):4555-4562. PubMed ID: 27527414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.
    Tay CM; Ong CW; Lee VK; Pang B
    Pathology; 2013 Feb; 45(2):127-37. PubMed ID: 23277171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Kondo T
    Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.
    Li B; Wang A; Liu J; Qi Z; Liu X; Yu K; Wu H; Chen C; Hu C; Wang W; Wu J; Hu Z; Ye L; Zou F; Liu F; Wang B; Wang L; Ren T; Zhang S; Bai M; Zhang S; Liu J; Liu Q
    J Med Chem; 2016 Sep; 59(18):8456-72. PubMed ID: 27545040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumour lacking mutations in the KIT and PDGFRA genes in a cat.
    Fujii Y; Iwasaki R; Ikeda S; Chimura S; Goto M; Yoshizaki K; Sakai H; Ito N; Mori T
    J Small Anim Pract; 2022 Mar; 63(3):239-243. PubMed ID: 34409605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
    Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
    Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the biology and therapy of gastrointestinal stromal tumors.
    D'Amato G; Steinert DM; McAuliffe JC; Trent JC
    Cancer Control; 2005; 12(1):44-56. PubMed ID: 15668652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
    Fernández A; Sanguino A; Peng Z; Crespo A; Ozturk E; Zhang X; Wang S; Bornmann W; Lopez-Berestein G
    Cancer Res; 2007 May; 67(9):4028-33. PubMed ID: 17483313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
    Alyuruk H; Calibasi G; Cavas L; Baskin Y; Oztop I; Ellidokuz H; Yilmaz U
    Eur J Cancer; 2013 Jul; 49(10):2449-52. PubMed ID: 23588081
    [No Abstract]   [Full Text] [Related]  

  • 20. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT; Tan KY
    World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.